Amsterdam, The Netherlands – 25 June 2019
Esperite N.V. (Euronext: ESP, “Esperite”) announces today that the negotiations with Polski Bank Komórek Macierzystych S.A. (WSE: PBKM, “PBKM”) regarding the proposed sale of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Sale) has been terminated by PBKM. The terms of the Proposed Sale agreed between the respective executive boards of the parties did not receive approval by the supervisory board of PBKM.
The board of directors of Esperite continues its evaluation of a broad range of strategic alternatives for its stem cell banking business and will seek reimbursement by PBKM for the legal costs incurred by Esperite during the negotiations of the Proposed Sale.
About ESPERITE
ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com.
***
This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).
Attachment
